Open Access
| Issue |
Med Sci (Paris)
Volume 36, Number 5, Mai 2020
|
|
|---|---|---|
| Page(s) | 447 - 448 | |
| Section | Le Magazine | |
| DOI | https://doi.org/10.1051/medsci/2020071 | |
| Published online | 26 May 2020 | |
- JésusP, FayemendyP, NicolM, et al. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol 2018 ; 25 : 97–104. [CrossRef] [PubMed] [Google Scholar]
- OlsenASB, FærgemanNJ. Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol 2017 ; 7 : 170069. [CrossRef] [PubMed] [Google Scholar]
- DodgeJC, TreleavenCM, PachecoJ, et al. Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2015 ; 112 : 8100–8105. [CrossRef] [Google Scholar]
- Henriques A, Croixmarie V, Bouscary A, et al. Sphingolipid metabolism is dysregulated at transcriptomic and metabolic levels in the spinal cord of an animal model of amyotrophic lateral sclerosis. Front Mol Neurosci 2018; 10. [Google Scholar]
- Henriques A, Huebecker M, Blasco H, et al. Inhibition of β-glucocerebrosidase activity preserves motor unit integrity in a mouse model of amyotrophic lateral sclerosis. Sci Rep 2017; 7. [Google Scholar]
- MalerbaM, RagnoliB. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol 2008 ; 4 : 1119–1129. [CrossRef] [PubMed] [Google Scholar]
- ShanmuganathanM, Britz-McKibbinP. Inhibitor screening of pharmacological chaperones for lysosomal β-glucocerebrosidase by capillary electrophoresis. Anal Bioanal Chem 2011 ; 399 : 2843–2853. [CrossRef] [PubMed] [Google Scholar]
- MaegawaGHB, TropakMB, ButtnerJD, et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 2009 ; 284 : 23502–23516. [CrossRef] [PubMed] [Google Scholar]
- NaritaA, ShiraiK, ItamuraS, et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study. Ann Clin and Transl Neurol 2016 ; 3 : 200–215. [CrossRef] [Google Scholar]
- Mullin S, Smith L, Lee K, et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol 2020; doi: 10.1001/jamaneurol.2019.4611. [Google Scholar]
- BouscaryA, QuessadaC, MosbachA, et al. Ambroxol hydrochloride improves motor functions and extends survival in a mouse model of familial amyotrophic lateral sclerosis. Front Pharmacol 2019 ; 10 : 883. [CrossRef] [PubMed] [Google Scholar]
- LedeenR, WuG, SonninoS, PrinettiA. Gangliosides of the nervous system. Gangliosides 2018 ; New York, NYSpringer19–55. [CrossRef] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.